Clinical features of lenvatinib treatment in elderly patients with advanced thyroid cancer

Suyama,Koichi; Fujiwara,Saori; Takeshita,Takashi; Sueta,Aiko; Inao,Touko; Yamamoto-Ibusuki,Mutsuko; Yamamoto,Yutaka; Iwase,Hirotaka

doi:10.3892/mco.2017.1265

July-2017 Volume 7 Issue 1

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

July-2017 Volume 7 Issue 1

Full Size Image

Article Open Access

Clinical features of lenvatinib treatment in elderly patients with advanced thyroid cancer

Authors:
- Koichi Suyama
- Saori Fujiwara
- Takashi Takeshita
- Aiko Sueta
- Touko Inao
- Mutsuko Yamamoto-Ibusuki
- Yutaka Yamamoto
- Hirotaka Iwase
View Affiliations / Copyright

Affiliations: Kumamoto University Hospital Cancer Center, Graduate School of Medical Sciences, Kumamoto University, Kumamoto 860-8556, Japan, Department of Breast and Endocrine Surgery, Kumamoto University, Kumamoto 860-8556, Japan

Copyright: © Suyama et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Pages: 24-26
|
Published online on: May 17, 2017

https://doi.org/10.3892/mco.2017.1265
Expand metrics +

Abstract

Until recently, there had not been an effective systemic chemotherapy for advanced differentiated thyroid carcinoma (DTC); lenvatinib, a multi-tyrosine kinase inhibitor, has been proven effective for DTC, but has also been revealed to have adverse side effects including hypertension, hand-foot syndrome (HFS) and diarrhea. There have been few clinical studies focused on the characteristics, safety concerns or precautions for lenvatinib treatment in elderly patients. The present study administered lenvatinib to 18 patients with DTC in Kumamoto University Hospital (Kumamoto, Japan), with 9 patients in both the younger group (<75 years old) and elderly group (≥75 years old). The median maximum systolic blood pressure (sBP) was significantly different between the two groups (158 mmHg in the younger group vs. 173 mmHg in the elderly group; P=0.042). There were no significant differences in median maximum diastolic blood pressure (94 vs. 95 mmHg; P=1.00), median degree of sBP elevation (43 vs. 55 mmHg; P=0.199) or median days until hypertension diagnosis (2.11 vs. 2.33 days; P=0.436). There were also no significant differences in other toxicities (HFS, proteinuria or diarrhea). In conclusion, lenvatinib should be introduced carefully to elderly patients with DTC, as they tend to present with hypertension during treatment. However, there were no differences in other toxicities between the younger and elderly groups; lenvatinib was fully tolerated in patients with DTC >75 years old.

View Figures

View References

1	Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO, et al: Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 372:621–630. 2015. View Article : Google Scholar : PubMed/NCBI
2	Boss DS, Glen H, Beijnen JH, Keesen M, Morrison R, Tait B, Copalu W, Mazur A, Wanders J, OBrien JP, et al: A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours. Br J Cancer. 106:1598–1604. 2012. View Article : Google Scholar : PubMed/NCBI
3	Nakamichi S, Nokihara H, Yamamoto N, Yamada Y, Honda K, Tamura Y, Wakui H, Sasaki T, Yusa W, Fujino K and Tamura T: A phase 1 study of lenvatinib, multiple receptor tyrosine kinase inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol. 76:1153–1161. 2015. View Article : Google Scholar : PubMed/NCBI
4	Cabanillas ME, Schlumberger M, Jarzab B, Martins RG, Pacini F, Robinson B, McCaffrey JC, Shah MH, Bodenner DL, Topliss D, et al: A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: a clinical outcomes and biomarker assessment. Cancer. 121:2749–2756. 2015. View Article : Google Scholar : PubMed/NCBI
5	Zhu C, Ma X, Hu Y, Guo L, Chen B, Shen K and Xiao Y: Safety and efficacy profile of lenvatinib in cancer therapy: a systematic review and meta-analysis. Oncotarget. 7:44545–44557. 2016.PubMed/NCBI
6	Chrischilles EA, Pendergast JF, Kahn KL, Wallace RB, Moga DC, Harrington DP, Kiefe CI, Weeks JC, West DW, Zafar SY and Fletcher RH: Adverse events among the elderly receiving chemotherapy for advanced non-small-cell lung cancer. J Clin Oncol. 28:620–627. 2010. View Article : Google Scholar : PubMed/NCBI
7	Townsley CA, Selby R and Siu LL: Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. J Clin Oncol. 23:3112–3124. 2005. View Article : Google Scholar : PubMed/NCBI
8	Clough-Gorr KM, Stuck AE, Thwin SS and Silliman RA: Older breast cancer survivors: geriatric assessment domains are associated with poor tolerance of treatment adverse effects and predict mortality over 7 years of follow-up. J Clin Oncol. 28:380–386. 2010. View Article : Google Scholar : PubMed/NCBI
9	US Department of Health and Human Services, . National Cancer Institute Common Terminology Criteria for Adverse Events v4.0. https://evs.nci.nih.gov/ftp1/CTCAE/Archive/CTCAE_4.02 _2009-09-15_QuickRef erence_5x7_Locked.pdfSeptember 1–2016
10	Keizer RJ, Gupta A, Mac Gillavry MR, Jansen M, Wanders J, Beijnen JH, Schellens JH, Karlsson MO and Huitema AD: A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080. J Pharmacokinet Pharmacodyn. 37:347–363. 2010. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Clinical features of lenvatinib treatment in elderly patients with advanced thyroid cancer

This article is mentioned in:

Abstract

Figure 1

Related Articles